MarketPeel
Insider Trading Intelligence
JL

Jeremy M. Levin

OVID
CEO · OVID THERAPEUTICS INC. · CIK 0001256153
FILING MIX · LIFETIME74%/26%
BUYS
14
SELLS
5
TOTAL VALUE
$166.2K
COMPANIES
1
ACTIVE SINCE
Sep 2019
HOLDINGS NOW
3,735,048
AVG SELL PX
TRADE KIND
SHOWING 19 / 19
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jeremy M. Levin, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+20.00%-9.87%-1.29%-8.57%-16.95%
14d5+80.00%+6.92%-0.47%+7.39%+7.70%
30d5+100.00%+3.68%-0.91%+4.59%+0.50%
60d5+20.00%-0.26%+0.43%-0.69%-4.94%
90d5+80.00%+1.57%+0.99%+0.58%+27.32%
180d5+0.00%-52.09%+8.88%-63.40%-63.40%
1y5(3 pending)+0.00%-61.43%+20.40%-81.83%-81.83%
2y5(3 pending)+0.00%-40.07%+24.41%-64.48%-64.48%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OVID · 3,735,048 shares · as of Mar 23, 2026
01,448,1332,896,2654,344,3985,792,5302020202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2019
2019
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 14 buys / 5 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OVID
OVID THERAPEUTICS INC.
SALE
Executive Chairman
47,3330Mar 23, 2026Mar 25, 2026View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
Executive Chairman
47,333$1.40$66.3K3,735,048Mar 23, 2026Mar 25, 2026View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
957,000957,000Feb 26, 2026Mar 2, 2026View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
71,0003,687,715Dec 15, 2025Dec 18, 2025View →
OVID
OVID THERAPEUTICS INC.
SALE
CEO
710Dec 15, 2025Dec 18, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
35,50035,500Dec 11, 2025Dec 18, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
7171Dec 11, 2025Dec 18, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
47,33347,333Dec 11, 2025Dec 18, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
1,650,0001,650,000Feb 20, 2025Feb 24, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
18,248$2.76$50.4K3,616,715Mar 18, 2024Mar 20, 2024View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
700,000700,000Feb 22, 2024Feb 26, 2024View →
OVID
OVID THERAPEUTICS INC.
SALEGRANT
Gift
573,2754,171,742Dec 4, 2023Dec 6, 2023View →
OVID
OVID THERAPEUTICS INC.
SALEGRANT
Gift
573,2753,598,467Dec 4, 2023Dec 6, 2023View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
600,000600,000Feb 23, 2023Feb 27, 2023View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
423,244423,244Apr 8, 2022Apr 12, 2022View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
600,000600,000Feb 3, 2022Feb 4, 2022View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
650,000650,000Dec 17, 2020Dec 21, 2020View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
CEO
8,488$5.84$49.6K5,792,530Aug 28, 2020Sep 1, 2020View →
OVID
OVID THERAPEUTICS INC.
SALEGRANT
Gift
465,1160Sep 20, 2019Feb 14, 2024View →
Other insiders · OVID
Loading peer insiders…
About this filer
CIK 0001256153
ROLE
CEO
PRIMARY
OVID
COMPANIES
1
ACTIVE SINCE
Sep 2019
MARKETPEEL · /INSIDER/0001256153DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback